SB269970 HCl

SB269970 HCl is a potent and selective antagonist of 5-HT7 receptor with pKi value of 8.3 [1].

SB269970 is a selective antagonist of 5-HT7 receptor. It shows at least 100-fold selective against 5-HT7 over a variety of receptors and enzymes. SB269970 prevents 5-CT from binding to h5-HT7(a) in H293 cells and human cloned 5-HT7 receptor in guinea-pig cerebral cortex membranes with pKi values of 8.9 and 8.3, respectively. SB269970 also inhibits adenylyl cyclase activity stimulated by 5-CT both in 5-HT7(a)/ HEK293 (pA2 of 8.5) membranes and in guinea-pig hippocampus (pKB of 8.3). In vehicle-treated animals, SB269970 almost completely inhibits the 5-CT-induced hypothermia with ED50 value of 2.96mg/kg [1].

References:
[1] Hagan J J, Price G W, Jeffrey P, et al. Characterization of SB-269970-A, a selective 5-HT7 receptor antagonist. British journal of pharmacology, 2000, 130(3): 539-548.

Comparative plasma and tissue distribution of Sun Pharma's generic doxorubicin HCl liposome injection versus Caelyx((R)) (doxorubicin HCl liposome injection) in syngeneic fibrosarcoma-bearing BALB/c mice and Sprague-Dawley rats.[Pubmed:28349166]

Cancer Chemother Pharmacol. 2017 May;79(5):899-913.

PURPOSE: The liposomal formulation of doxorubicin [doxorubicin (DXR) hydrochloride (HCl) liposome injection, Caelyx((R))] alters the tissue distribution of DXR as compared with nonliposomal DXR, resulting in an improved benefit-risk profile. We conducted studies in murine models to compare the plasma and tissue distribution of a proposed generic DXR HCl liposome injection developed by Sun Pharmaceuticals Industries Limited (SPIL DXR HCl liposome injection) with Caelyx((R)). METHODS: The plasma and tissue distributions of the SPIL and reference DXR HCl liposome injections were compared in syngeneic fibrosarcoma-bearing BALB/c mice and Sprague-Dawley rats. Different batches and different lots of the same batch of the reference product were also compared with each other. RESULTS: The SPIL and reference DXR HCl liposome injections exhibited generally comparable plasma and tissue distribution profiles in both models. While minor differences were observed between the two products in some tissues, different batches and lots of the reference product also showed some differences in the distribution of various analytes in some tissues. The ratios of estimated free to encapsulated DXR for plasma and tissue were generally comparable between the SPIL and reference DXR HCl liposome injections in both models, indicating similar extents of absorption into the tissues and similar rates of drug release from liposomes. CONCLUSIONS: The plasma and tissue distribution profiles of the SPIL and reference DXR HCl liposome injections were shown to be generally comparable. Inconsistencies between the products observed in some tissues were thought to be due to biological variation.

The risk reduction of recurrent periodontal pathogens of local application minocycline HCl 2% gel, used as an adjunct to scaling and root planing for chronic periodontitis treatment.[Pubmed:28331333]

Ther Clin Risk Manag. 2017 Mar 10;13:307-314.

BACKGROUND: The aim of this study was to evaluate the clinical and microbiological effects of local application minocycline HCl 2% gel, used as an adjunct to scaling and root planing (SRP) for treatment of chronic periodontitis (CP). CP is an inflammation of periodontal tissue that is caused mainly by bacterial infection, where periodontal destruction such as loss of attachment and bone destruction occurred. METHODS: A total of 81 subjects with moderate to severe periodontitis whose baseline clinical attachment loss (CAL) was >/=4 mm were randomly assigned to receive SRP alone (control group, N=39) or SRP followed by four times of local application of minocycline HCl gel (Periocline) once a week (test group, N=42). Pocket depth, CAL, and papilla bleeding index were examined at baseline, 21 days, 2, 3, and 6 months. Subgingival plaque samples were collected with sterile curettes and were analyzed by real-time polymerase chain reaction for the presence of three periodontal pathogens (Porphyromonas gingivalis [P.g.], Tannerella forsythia [T.f.], and Treponema denticola [T.d.]) at baseline, 2, 3, and 6 months. RESULTS: The number of bacteria was reduced in both groups at 2 months after baseline (SRP treatment). The changes (2-6 months) in T.d. and T.f. counts in the test group were significantly lower than those in the control group. In the control group, a significant regrowth of P.g., T.f., and T.d. was observed from 2 to 6 months and of P.g. and T.f. from 3 to 6 months. On the other hand, in the test group, the number of the three bacteria did not significantly increase during the 6-month period. CONCLUSION: The results showed that local application of minocycline, used as an adjunct to SRP, was effective for suppressing regrowth of periodontal pathogens, suggesting its risk reduction of recurrent periodontal pathogens in CP.

Effects of anabolic implants and ractopamine-HCl on muscle fiber morphometrics, collagen solubility, and tenderness of beef longissimus lumborum steaks.[Pubmed:28380530]

J Anim Sci. 2017 Mar;95(3):1219-1231.

The objective of this study was to examine the effects of growth-promoting technologies (GP) and postmortem aging on longissimus lumborum muscle fiber cross-sectional area (CSA), collagen solubility, and their relationship to meat tenderness. Two groups of black-hided crossbred feedlot heifers (group 1: = 33, initial BW 430 +/- 7 kg; group 2: = 32, initial BW 466 +/- 7 kg) were blocked by BW and assigned to 1 of 3 treatments consisting of: no implant and no ractopamine hydrochloride (CON; = 21); implant, no ractopamine hydrochloride (IMP; = 22); implant and ractopamine hydrochloride (COMBO; = 22). Heifers that received an implant were administered an implant containing 200 mg trenbolone acetate and 20 mg estradiol on d 0 of the study, and heifers in the COMBO group received 400 mgheadd of ractopamine hydrochloride for 28 (Group 1) or 29 d (Group 2) at the end of 90- (Group 1) or 106-d (Group 2) feeding period. Following harvest, strip loins were collected and further fabricated into 5 roasts for postmortem aging (DOA) periods of 2, 7, 14, 21, or 35 d. After aging, Warner-Bratzler shear force (WBSF), muscle fiber CSA, and collagen solubility were measured. There was no treatment x DOA interaction for WBSF ( = 0.86), but treatment and DOA impacted WBSF ( < 0.01). Over the entire aging study, COMBO steaks had greater ( < 0.01) shear force values when compared to CON steaks. The IMP steaks tended to have decreased ( = 0.07) shear force when compared to the COMBO steaks, but did not differ ( = 0.11) from CON steaks. The IMP and COMBO treatments had increased type IIA fiber CSA when compared to CON ( < 0.01). When compared to each other, the IMP and COMBO type IIA fiber CSA did not differ ( = 0.76). Type I and IIX fiber CSA tended to be greater than CON for IMP and COMBO treatments ( < 0.10). There was no treatment x DOA interaction for all collagen measures ( > 0.33). Collagen amounts were not impacted by GP treatment ( > 0.72), but DOA increased the concentration of soluble collagen ( = 0.04). Fiber CSA of all fiber types were positively correlated ( < 0.05; = 0.21 to 0.28) with WBSF only on d 2 of aging, while soluble collagen amount tended to negatively correlate with WBSF on d 7 and 14 of aging ( < 0.10; = -0.24 and -0.23, respectively). Administration of GP during heifer finishing resulted in greater steak WBSF over 35 d of aging, which was not due to collagen characteristics and only minimally affected by fiber CSA.

Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid alpha-Glucosidase in Pompe Patients Co-administered with Alglucosidase alpha.[Pubmed:28341561]

Mol Ther. 2017 May 3;25(5):1199-1208.

Duvoglustat HCl (AT2220, 1-deoxynojirimycin) is an investigational pharmacological chaperone for the treatment of acid alpha-glucosidase (GAA) deficiency, which leads to the lysosomal storage disorder Pompe disease, which is characterized by progressive accumulation of lysosomal glycogen primarily in heart and skeletal muscles. The current standard of care is enzyme replacement therapy with recombinant human GAA (alglucosidase alfa [AA], Genzyme). Based on preclinical data, oral co-administration of duvoglustat HCl with AA increases exposure of active levels in plasma and skeletal muscles, leading to greater substrate reduction in muscle. This phase 2a study consisted of an open-label, fixed-treatment sequence that evaluated the effect of single oral doses of 50 mg, 100 mg, 250 mg, or 600 mg duvoglustat HCl on the pharmacokinetics and tissue levels of intravenously infused AA (20 mg/kg) in Pompe patients. AA alone resulted in increases in total GAA activity and protein in plasma compared to baseline. Following co-administration with duvoglustat HCl, total GAA activity and protein in plasma were further increased 1.2- to 2.8-fold compared to AA alone in all 25 Pompe patients; importantly, muscle GAA activity was increased for all co-administration treatments from day 3 biopsy specimens. No duvoglustat-related adverse events or drug-related tolerability issues were identified.

DR4004, a putative 5-HT(7) receptor antagonist, also has functional activity at the dopamine D2 receptor.[Pubmed:12163113]

Eur J Pharmacol. 2002 Aug 2;449(1-2):105-11.

The tetrahydrobenzindole, 2a-(4-(4-phenyl-1,2,3,6-tetrahydropyridyl)butyl)-2a,3,4,5-tetrahydrobenzo[cd]indo l-2(1H)-one (DR4004) has been described as a highly selective antagonist for the 5-hydroxytryptamine(7) (5-HT(7)) receptor [J. Med. Chem. 42 (1999) 533]. Consistent with original data, DR4004 bound to rat hypothalamic membranes with an affinity of 7.3+/-0.2 (pK(i)+/-S.E.M.) for the 5-HT(7) receptor. However, competition binding studies showed that DR4004 had poor receptor selectivity with the following affinity profile; dopamine D2 receptor, alpha(1)-adrenoceptor > or =5-HT(7) receptor>histamine H(1) receptor, alpha(2)-adrenoceptor>dopamine D1 receptor>beta-adrenoceptor, muscarinic and 5-HT(2A/C) receptors. In conscious rats DR4004 (1, 5 or 10 mg/kg i.p.) produced a dose-dependent hyperglycaemia and hypothermia, but the former was reduced by the dopamine D2 receptor antagonist raclopride. Another 5-HT(7) receptor antagonist, (R)-3-(2-(2-(4-methylpiperidin-1-yl)-ethyl)pyrrolidine-1-sulfonyl)phenol (SB-269970) produced hypothermia but no hyperglycaemia. This study confirms that DR4004 has high affinity for the 5-HT(7) receptor but suggests that dopamine D2 receptor activity contributes to some of the in vivo effects.

Characterization of SB-269970-A, a selective 5-HT(7) receptor antagonist.[Pubmed:10821781]

Br J Pharmacol. 2000 Jun;130(3):539-48.

The novel 5-HT(7) receptor antagonist, SB-269970-A, potently displaced [(3)H]-5-CT from human 5-HT(7(a)) (pK(i) 8.9+/-0.1) and 5-HT(7) receptors in guinea-pig cortex (pK(i) 8.3+/-0.2). 5-CT stimulated adenylyl cyclase activity in 5-HT(7(a))/HEK293 membranes (pEC(50) 7.5+/-0.1) and SB-269970-A (0.03 - 1 microM) inhibited the 5-CT concentration-response with no significant alteration in the maximal response. The pA(2) (8.5+/-0.2) for SB-269970-A agreed well with the pK(i) determined from [(3)H]-5-CT binding studies. 5-CT-stimulated adenylyl cyclase activity in guinea-pig hippocampal membranes (pEC(50) of 8.4+/-0.2) was inhibited by SB-269970-A (0.3 microM) with a pK(B) (8.3+/-0.1) in good agreement with its antagonist potency at the human cloned 5-HT(7(a)) receptor and its binding affinity at guinea-pig cortical membranes. 5-HT(7) receptor mRNA was highly expressed in human hypothalamus, amygdala, thalamus, hippocampus and testis. SB-269970-A was CNS penetrant (steady-state brain : blood ratio of ca. 0.83 : 1 in rats) but was rapidly cleared from the blood (CLb=ca. 140 ml min(-1) kg(-1)). Following a single dose (3 mg kg(-1)) SB-269970 was detectable in rat brain at 30 (87 nM) and 60 min (58 nM). In guinea-pigs, brain levels averaged 31 and 51 nM respectively at 30 and 60 min after dosing, although the compound was undetectable in one of the three animals tested. 5-CT (0.3 mg kg(-1) i.p.) induced hypothermia in guinea-pigs was blocked by SB-269970-A (ED(50) 2.96 mg kg(-1) i.p.) and the non-selective 5-HT(7) receptor antagonist metergoline (0.3 - 3 mg kg(-1) s.c.), suggesting a role for 5-HT(7) receptor stimulation in 5-CT induced hypothermia in guinea-pigs. SB-269970-A (30 mg kg(-1)) administered at the start of the sleep period, significantly reduced time spent in Paradoxical Sleep (PS) during the first 3 h of EEG recording in conscious rats.

SB269970 hydrochloride (SB-269970A) is a hydrochloride salt form of SB-269970, which is a 5-HT7 receptor antagonist with the pKi of 8.3, exhibits >50-fold selectivity against other receptors.

SB269970 HCl,261901-57-9,Natural Products,5-HT Receptor, buy SB269970 HCl , SB269970 HCl supplier , purchase SB269970 HCl , SB269970 HCl cost , SB269970 HCl manufacturer , order SB269970 HCl , high purity SB269970 HCl